Abstract
Characterization of Parkinson’s disease (PD) progression using real-world evidence could guide clinical trial design and identify subpopulations. Efforts to curate research populations, the increasing availability of real-world data and recent advances in natural language processing, particularly large language models, allow for a more granular comparison of populations and the methods of data collection describing these populations than previously possible.
This study includes two research populations and two real-world data derived (RWD) populations. The research populations are the Harvard Biomarkers Study (HBS, N = 935), a longitudinal biomarkers cohort study with in-person structured study visits; and Fox Insights (N = 36,660), an online self-survey-based research study of the Michael J. Fox Foundation. Real-world cohorts are the Optum Integrated Claims-electronic health records (N = 157,475), representing wide-scale linked medical and claims data and de-identified data from Mass General Brigham (MGB, N = 22,949), an academic hospital system. Structured, de-identified electronic health records data at MGB are supplemented using natural language processing with a large language model to extract measurements of PD progression. This extraction process is manually validated for accuracy.
Motor and cognitive progression scores change more rapidly in MGB than HBS (median survival until H&Y 3: 5.6 years vs. >10, p<0.001; mini-mental state exam median decline 0.28 vs. 0.11, p<0.001; and clinically recognized cognitive decline, p=0.001). In the real-world populations, patients are diagnosed more than eleven years later (RWD mean of 72.2 vs. research mean of 60.4, p<0.001). After diagnosis, in real-world cohorts, treatment with PD medications is initiated 2.3 years later on average (95% CI: [2.1-2.4]; p<0.001).
This study provides a detailed characterization of Parkinson’s progression in diverse populations. It delineates systemic divergences in the patient populations enrolled in research settings vs. patients in the real world. These divergences are likely due to a combination of selection bias and real population differences, but exact attribution of the causes is challenging using existing data. This study emphasizes a need to utilize multiple data sources and to diligently consider potential biases when planning, choosing data sources, and performing downstream tasks and analyses.
Competing Interest Statement
FF, SB, KJC, MJP, CC, DK, CC are employees of Sanofi and may hold shares and/or stock options in the company. All authors declare no other competing financial or non-financial interests.
Funding Statement
This work was funded in part by the Sanofi iDEA Awards Initiative (BKB) as well the National Institute of Neurological Disorders and Stroke grant number (K99NS114850, R00NS114850). CRS's work is supported in part by NIH grants NINDS/NIA R01NS115144, U01NS095736, U01NS100603, the U.S. Department of Defense, and the American Parkinson Disease Association Center for Advanced Parkinson Research. The Fox Insight Study (FI) is funded by The Michael J. Fox Foundation for Parkinson's Research. This research was funded in part by Aligning Science Across Parkinson's [ASAP-000301] through the Michael J. Fox Foundation for Parkinson's Research (MJFF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Mass General Brigham Institutional Review Board (#2017P002452). This study received only de-identified, retrospective data from research datasets (HBS and Fox). Research dataset participants are consented for study and publication as part of the recruitment process. Real world datasets (MGB and Optum) are retrospective de-identified data and therefore individual consent is not required for publication.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Authors had primary access to all data sources used in this study (BKB). All data used in this study are secondary use and therefore the authors must direct those interested in using any data involved to their source:
Harvard Biomarkers set is accessible through Accelerating Medicines Partnership program for Parkinson’s disease https://amp-pd.org/unified-cohorts/hbs and through https://www.bwhparkinsoncenter.org/biobank/
Mass General Brigham EMR; https://rc.partners.org/about/who-we-are-risc/research-patient-data-registry
Optum® Integrated Claims-EHR Data44 (https://www.optum.com/content/dam/optum3/optum/en/resources/fact-sheets/Integrated-Data-product-sheet.pdf),
Fox Insight43 https://foxinsight.michaeljfox.org/
